Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05794594
Other study ID # CHChongqingMU-2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2015
Est. completion date March 1, 2023

Study information

Verified date March 2023
Source Children's Hospital of Chongqing Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this type of observational study is to investigate the preliminary effect of 3D printed personalized extendable prosthesis replacement on limb salvage in children with osteosarcoma. The main question it aims to answer is: Is 3D printed personalized extendable prosthesis replacement has a good outcome in limb salvage pediatric osteosarcoma?


Description:

Osteosarcoma is one of the most common primary malignant bone tumors in children and adolescents. In this study, the investigators try to investigate the preliminary effect of 3D printed personalized extendable prosthesis replacement on limb salvage in children with osteosarcoma.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date March 1, 2023
Est. primary completion date January 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria: - tumors of the extremities, with moderate soft-tissue invasion - the neurovascular bundle is not invaded, and the tumor can be excised totally - no metastatic lesions or metastases can be cured Exclusion Criteria: - recurrent tumors - poorly differentiated tumors - poor soft-tissue conditions - neurovascular invasion around tumors - ineffective chemotherapy with metastasis

Study Design


Related Conditions & MeSH terms


Intervention

Device:
3D printed personalized extendable prosthesis
3D printed personalized extendable prosthesis replacement for limb preservation in children

Locations

Country Name City State
China Children's Hospital of Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Yuxi Su

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence Osteosarcoma recurrence rate 7years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03628209 - Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Phase 1/Phase 2
Suspended NCT05558280 - Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma Phase 2
Completed NCT04644913 - Long-term Evaluation of the Quality of Life of Former Patients Treated With Orthopedic Surgery, With or Without Radiotherapy
Active, not recruiting NCT04803877 - SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma Phase 2
Not yet recruiting NCT06341712 - Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma Phase 2
Terminated NCT03139318 - Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity N/A
Recruiting NCT05107843 - Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas